Advanced Solid Tumors Clinical Trials in San Antonio, Texas

33 studies are recruiting for advanced solid tumors in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START San Antonio, San Antonio, Texas

   Locations

   47 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06004245 on ClinicalTrials.gov

2. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT, San Antonio, Texas

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

3. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology, San Antonio, Texas

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

4. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

   The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology - San Antonio, San Antonio, Texas

   Locations

   20 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06657222 on ClinicalTrials.gov

5. A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

   The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-428 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or other DDR deficiencies or high replication stress, and to determine the maximum tolerated dose (MTD…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - San Antonio, San Antonio, Texas

   Locations

   8 in total

   Run by

   FoRx Therapeutics AG

   See if you can join NCT07356453 on ClinicalTrials.gov

6. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

   The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Oncology - PARENT, San Antonio, Texas

   Locations

   9 in total

   Run by

   EMD Serono Research & Development Institute, Inc.

   See if you can join NCT07360314 on ClinicalTrials.gov

7. A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

   The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with stand…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, San Antonio, Texas

   Locations

   11 in total

   Run by

   AstraZeneca

   See if you can join NCT07161414 on ClinicalTrials.gov

8. First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors

   This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion uses Bayesian optimal interval (BOIN) design to escalate and determine the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Next Oncology - Oncology, San Antonio, Texas

   Locations

   12 in total

   Run by

   VelaVigo Bio Inc

   See if you can join NCT07700160 on ClinicalTrials.gov

9. A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

   This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Health San Antonio - Mays Cancer Center, San Antonio, Texas

   Locations

   17 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06792552 on ClinicalTrials.gov

10. Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

    This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evaluate the safety and tolerability of YL211 as monotherapy in patients with selected advanced solid tu…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT San Antonio, San Antonio, Texas

    Locations

    21 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06384352 on ClinicalTrials.gov

11. A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

    The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processe…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics (START), San Antonio, Texas

    Locations

    14 in total

    Run by

    Ottimo Pharma Limited

    See if you can join NCT07266428 on ClinicalTrials.gov

12. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Center for Cancer Research - San Antonio, San Antonio, Texas

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

13. A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

    This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    5 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT07372625 on ClinicalTrials.gov

14. A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

    This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UT Health Mays Cancer Center, San Antonio, Texas

    Locations

    19 in total

    Run by

    Marengo Therapeutics, Inc.

    See if you can join NCT05592626 on ClinicalTrials.gov

15. A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

    The purpose of this study is to assess the safety and tolerability of mRNA-4106 monotherapy and of mRNA-4200 in combination with checkpoint inhibitor therapy in participants with solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START San Antonio, San Antonio, Texas

    Locations

    4 in total

    Run by

    ModernaTX, Inc.

    See if you can join NCT06880549 on ClinicalTrials.gov

16. A Study of PHN-012 in Patients With Advanced Solid Tumors

    This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    PHN-012-001 Site, San Antonio, Texas

    Locations

    26 in total

    Run by

    Pheon Therapeutics

    See if you can join NCT07127874 on ClinicalTrials.gov

17. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    9 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07397338 on ClinicalTrials.gov

18. Study of GS-2426 in Participants With Advanced Solid Tumors

    The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in p…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START San Antonio, LLC, San Antonio, Texas

    Locations

    4 in total

    Run by

    Gilead Sciences

    See if you can join NCT07601243 on ClinicalTrials.gov

19. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

    To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    South Texas Accelerated Research Therapeutics, San Antonio, Texas

    Locations

    39 in total

    Run by

    Incyte Corporation

    See if you can join NCT05836324 on ClinicalTrials.gov

20. A Study of Safety, Tolerability and Preliminary Efficacy of NTS071 in Subjects With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

    This study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology, San Antonio, Texas

    Locations

    2 in total

    Run by

    Nutshell Therapeutics (Shanghai) Co., LTD.

    See if you can join NCT07060989 on ClinicalTrials.gov

21. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START, San Antonio, Texas

    Locations

    15 in total

    Run by

    Ensem Therapeutics

    See if you can join NCT06993844 on ClinicalTrials.gov

22. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site #2, San Antonio, Texas

    Locations

    12 in total

    Run by

    Alterome Therapeutics, Inc.

    See if you can join NCT06835569 on ClinicalTrials.gov

23. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START, San Antonio, Texas

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

24. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology, San Antonio, Texas

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

25. A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

    This study is researching an experimental drug called REGN10597 alone or in combination with another drug called cemiplimab (called "study drug(s)"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe, tolerable, and eff…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Next Oncology, San Antonio, Texas

    Locations

    11 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT06413680 on ClinicalTrials.gov